ReviewCurrent rheumatology reviews2026
Hyperbaric Oxygen Therapy as a Therapeutic Option for Patients with Fibromyalgia.
Review in Current rheumatology reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION/
objectiveThis narrative review has briefly outlined the mechanisms of action underlying the therapeutic effects of hyperbaric oxygen (HBO). It was designed to provide researchers and healthcare professionals with a broad overview of the benefits and potential drawbacks of using HBO in FM patients.
methodsFor this review, we searched PubMed/Medline, Cochrane Library, Embase, and Google Scholar databases for articles published between 2000 and 2023, using the following search terms: "hyperbaric oxygen therapy", "fibromyalgia", and "physical exercise".
resultsIn total, more than 90 publications were retrieved, 45 of which were analyzed in depth. The majority of the studies retrieved were of an observational design, whereas there were only a few randomized trials and very few reviews. Based on the compiled literature, there is further support for the hypothesis that reduced oxygen availability may be at the origin of the structural degeneration observed in the muscles of FM patients. In the absence of a universally accepted cure for FM, the therapeutic approach must be multidisciplinary and multimodal. It should be noted that many questions remain unanswered. What is the optimal dose-response range, duration of treatment, and associated economic cost? Larger controlled trials are needed to determine the exact role of HBO as an adjuvant therapy for FM patients.
conclusionBased on the published literature, repeated exposure to HBO may be a promising therapeutic adjunct for FM patients. However, more clinical research is needed before HBO can be established as a reliable approach for FM patients.
Indexed as
Identifiers
40626530What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.